ATE256473T1 - Konjugate welche bei der behandlung von prostatakrebs nützlich sind - Google Patents
Konjugate welche bei der behandlung von prostatakrebs nützlich sindInfo
- Publication number
- ATE256473T1 ATE256473T1 AT98934444T AT98934444T ATE256473T1 AT E256473 T1 ATE256473 T1 AT E256473T1 AT 98934444 T AT98934444 T AT 98934444T AT 98934444 T AT98934444 T AT 98934444T AT E256473 T1 ATE256473 T1 AT E256473T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- treatment
- prostate cancer
- conjugates useful
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5219597P | 1997-07-10 | 1997-07-10 | |
| GBGB9810183.5A GB9810183D0 (en) | 1998-05-13 | 1998-05-13 | Conjugates useful in the treatment of prostate cancer |
| PCT/US1998/014413 WO1999002175A1 (en) | 1997-07-10 | 1998-07-09 | Conjugates useful in the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE256473T1 true ATE256473T1 (de) | 2004-01-15 |
Family
ID=26313662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98934444T ATE256473T1 (de) | 1997-07-10 | 1998-07-09 | Konjugate welche bei der behandlung von prostatakrebs nützlich sind |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1009420B1 (de) |
| JP (1) | JP2002510325A (de) |
| AT (1) | ATE256473T1 (de) |
| AU (1) | AU740597B2 (de) |
| CA (1) | CA2295860A1 (de) |
| DE (1) | DE69820644D1 (de) |
| WO (1) | WO1999002175A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504014B1 (en) | 1997-05-19 | 2003-01-07 | The John Hopkins University | Tissue specific prodrug |
| US6545131B1 (en) | 1997-05-19 | 2003-04-08 | The Johns Hopkins University | Tissue specific prodrug |
| WO1998052966A1 (en) | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| WO2000033888A2 (en) * | 1998-12-11 | 2000-06-15 | Coulter Pharmaceutical, Inc. | Prodrug compounds and process for preparation thereof |
| GB9924759D0 (en) * | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
| PL360826A1 (en) | 2000-03-15 | 2004-09-20 | Bristol-Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| EP2518142B1 (de) | 2001-08-24 | 2015-07-15 | UVic Industry Partnerships Inc. | Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs |
| DE602006020867D1 (de) | 2005-06-14 | 2011-05-05 | Protox Therapeutics Inc | Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine |
| EP1900742A1 (de) | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Konjugate von Disorazol und seinen Derivaten mit Zell-bindenden Molekülen, neue Disorazolderivate, Verfahren zu deren Herstellung und deren Verwendung |
| BRPI1009521A2 (pt) * | 2009-03-09 | 2016-03-15 | Ktb Tumorforschungs Gmbh | pró-drogas. |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| HUE054131T2 (hu) | 2015-11-19 | 2021-08-30 | Revitope Ltd | Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben |
| CA3203072A1 (en) | 2020-12-22 | 2022-06-30 | Andrea CASAZZA | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
| US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
-
1998
- 1998-07-09 JP JP50900399A patent/JP2002510325A/ja active Pending
- 1998-07-09 AT AT98934444T patent/ATE256473T1/de not_active IP Right Cessation
- 1998-07-09 EP EP98934444A patent/EP1009420B1/de not_active Expired - Lifetime
- 1998-07-09 AU AU83960/98A patent/AU740597B2/en not_active Ceased
- 1998-07-09 WO PCT/US1998/014413 patent/WO1999002175A1/en active IP Right Grant
- 1998-07-09 DE DE69820644T patent/DE69820644D1/de not_active Expired - Lifetime
- 1998-07-09 CA CA002295860A patent/CA2295860A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1009420B1 (de) | 2003-12-17 |
| AU740597B2 (en) | 2001-11-08 |
| CA2295860A1 (en) | 1999-01-21 |
| AU8396098A (en) | 1999-02-08 |
| JP2002510325A (ja) | 2002-04-02 |
| EP1009420A4 (de) | 2002-01-23 |
| WO1999002175A1 (en) | 1999-01-21 |
| DE69820644D1 (de) | 2004-01-29 |
| EP1009420A1 (de) | 2000-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE256473T1 (de) | Konjugate welche bei der behandlung von prostatakrebs nützlich sind | |
| WO1998018493A3 (en) | Conjugates useful in the treatment of prostate cancer | |
| DK0771209T3 (da) | Hidtil ukendte peptider | |
| ATE460429T1 (de) | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb | |
| DK1124568T3 (da) | Polyspecifikke bindingsmolekyler og anvendelser deraf | |
| DK1171417T3 (da) | Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf | |
| NO20031048L (no) | "Pseudo"-nativ kjemisk ligering | |
| EP1363920A4 (de) | Modifizierte psma-liganden und deren verwendung | |
| DE69838177D1 (de) | Androgensyntheseinhibitoren | |
| ATE374822T1 (de) | Mutanter apre promoter | |
| DK1414956T3 (da) | Höjt påvirkningsresistente granula | |
| ATE394484T1 (de) | Smad 6 und dessen anwendungen | |
| AU4927501A (en) | Prostate cancer markers | |
| BG104563A (en) | Conjugates useful in the treatment of prostate cancer | |
| FR2766193B1 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| TR199902751T2 (xx) | Proteaz inhibit�rleri. | |
| DK0863857T3 (da) | Fremgangsmåde til perfluoralkylering og reaktant til iværksættelse af denne fremgangsmåde | |
| WO1999044628A8 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB0024351D0 (en) | Dye-labelled peptide and method | |
| ATE224387T1 (de) | N-(pyridinylamino)isoindoline und verwandte verbindungen | |
| ECSP972297A (es) | Conjugados utiles en el tratamiento de cancer de prostata | |
| DE60120187D1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| ZA991319B (en) | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
| TR199900652T2 (xx) | Deterjan bile�imleri |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |